CN103957922A - 含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物 - Google Patents

含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物 Download PDF

Info

Publication number
CN103957922A
CN103957922A CN201280034191.2A CN201280034191A CN103957922A CN 103957922 A CN103957922 A CN 103957922A CN 201280034191 A CN201280034191 A CN 201280034191A CN 103957922 A CN103957922 A CN 103957922A
Authority
CN
China
Prior art keywords
pvp
ophthalmic composition
steroid
compositions
month
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280034191.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.斯泰因
M.维塞尔
J.卡普里奥蒂
B.梁
C.M.萨姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foresight Biotherapeutics Inc
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47139697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103957922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of CN103957922A publication Critical patent/CN103957922A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280034191.2A 2011-05-12 2012-05-11 含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物 Pending CN103957922A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485475P 2011-05-12 2011-05-12
US61/485475 2011-05-12
PCT/US2012/037563 WO2012155062A1 (en) 2011-05-12 2012-05-11 Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories

Publications (1)

Publication Number Publication Date
CN103957922A true CN103957922A (zh) 2014-07-30

Family

ID=47139697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280034191.2A Pending CN103957922A (zh) 2011-05-12 2012-05-11 含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物

Country Status (16)

Country Link
US (1) US20150038473A1 (enExample)
EP (1) EP2707006B1 (enExample)
JP (2) JP6072009B2 (enExample)
KR (1) KR101967938B1 (enExample)
CN (1) CN103957922A (enExample)
AR (1) AR086399A1 (enExample)
AU (3) AU2012253335B2 (enExample)
BR (1) BR112013028735A2 (enExample)
CA (1) CA2835343A1 (enExample)
CL (1) CL2013003016A1 (enExample)
CO (1) CO6821949A2 (enExample)
EC (1) ECSP13013069A (enExample)
MX (1) MX360666B (enExample)
PE (1) PE20141070A1 (enExample)
TW (2) TWI717552B (enExample)
WO (1) WO2012155062A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799179A (zh) * 2017-07-04 2020-02-14 富陆凯米有限责任公司 水溶性提高的包含碘试剂及氯化钠的固体组合物及包含其水溶液的眼、口腔、鼻腔或吸入用抗病毒及抗菌组合物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665195B2 (ja) 1995-05-19 1997-10-22 日本電気移動通信株式会社 Ｍｃａシステムにおける移動局の個別番号表示方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP6226998B2 (ja) 2013-02-15 2017-11-08 千寿製薬株式会社 抗菌性金属を含有するジフルプレドナートエマルション組成物
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
HK1248570A1 (zh) * 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
EP3416654B1 (en) 2016-02-18 2021-10-27 Invirsa, Inc. Medical use of 5'-adenosine diphosphate ribose (adpr)
US11040062B2 (en) 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
SG11201809811VA (en) * 2016-05-05 2018-12-28 Veloce Biopharma Llc Compositions and methods for treatment of inflammation or infection of the eye
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP4226971A1 (en) 2018-03-27 2023-08-16 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
CN113797162B (zh) * 2020-06-17 2023-05-05 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
CN112305115B (zh) * 2020-10-29 2022-08-23 诺峰药业(成都)有限公司 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法
KR20220062790A (ko) 2020-11-09 2022-05-17 정춘영 포비돈 아이오딘계 소독액
US20240082188A1 (en) * 2021-01-21 2024-03-14 Taejoon Pharmaceutical Co., Ltd. Ophthalmic composition
EP4282432A4 (en) * 2021-01-22 2025-01-29 Chengdu Ruimu Biopharmaceuticals Co., Ltd. CARRIER OR AUXILIARY SUBSTANCE FOR OPHTHALMIC PREPARATION, ITS PREPARATION METHOD AND ITS APPLICATION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400355A (zh) * 2006-03-14 2009-04-01 Cls制药公司 包含聚维酮碘的眼用组合物
WO2009151619A1 (en) * 2008-06-12 2009-12-17 Foresight Biotherapeutics, Inc. Povidone iodine, a novel alternative preservative for ophthalmic compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) * 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
JP2013514373A (ja) * 2009-12-15 2013-04-25 フォーサイト・バイオセラピューティクス・インコーポレーテッド 非刺激性の眼科用ポビドンヨード組成物
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400355A (zh) * 2006-03-14 2009-04-01 Cls制药公司 包含聚维酮碘的眼用组合物
WO2009151619A1 (en) * 2008-06-12 2009-12-17 Foresight Biotherapeutics, Inc. Povidone iodine, a novel alternative preservative for ophthalmic compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799179A (zh) * 2017-07-04 2020-02-14 富陆凯米有限责任公司 水溶性提高的包含碘试剂及氯化钠的固体组合物及包含其水溶液的眼、口腔、鼻腔或吸入用抗病毒及抗菌组合物

Also Published As

Publication number Publication date
JP6359619B2 (ja) 2018-07-18
AR086399A1 (es) 2013-12-11
KR20140045375A (ko) 2014-04-16
US20150038473A1 (en) 2015-02-05
TW201811340A (zh) 2018-04-01
CL2013003016A1 (es) 2014-05-02
EP2707006A4 (en) 2014-09-24
TWI632914B (zh) 2018-08-21
AU2012253335A1 (en) 2013-05-02
ECSP13013069A (es) 2015-03-31
JP2014516954A (ja) 2014-07-17
KR101967938B1 (ko) 2019-04-10
MX2013012971A (es) 2013-12-12
EP2707006B1 (en) 2019-07-03
PE20141070A1 (es) 2014-09-14
AU2018203492A1 (en) 2018-06-07
BR112013028735A2 (pt) 2017-12-05
CO6821949A2 (es) 2013-12-31
AU2016222491A1 (en) 2016-09-22
JP6072009B2 (ja) 2017-02-01
TWI717552B (zh) 2021-02-01
WO2012155062A1 (en) 2012-11-15
AU2012253335B2 (en) 2016-08-04
TW201311256A (zh) 2013-03-16
EP2707006A1 (en) 2014-03-19
JP2017095474A (ja) 2017-06-01
CA2835343A1 (en) 2012-11-15
MX360666B (es) 2018-11-13

Similar Documents

Publication Publication Date Title
CN103957922A (zh) 含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物
US9855295B2 (en) Methods of using ophthalmic compositions comprising povidone-iodine
US20250255809A1 (en) Ophthalmic pharmaceutical compositions of roflumilast
JP6320616B1 (ja) 新規眼科用組成物および使用方法
WO2019135779A1 (en) Novel ophthalmic composition and methods of use
HK1195002A (en) Stable povidone-iodine compositions with bromfenac
HK1195002B (en) Stable povidone-iodine compositions with bromfenac
NZ751841A (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
NZ751841B2 (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
NZ717573A (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
NZ717573B2 (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
JP2024501425A (ja) 眼炎症の有害作用を軽減するためのジフルプレドナート
US20190060224A1 (en) Novel ophthalmic composition and methods of use
HK1130665B (zh) 包含聚维酮碘的眼用组合物
US20210213045A1 (en) Novel ophthalmic composition and methods of use
EP3672572A1 (en) Novel ophthalmic composition and methods of use
US20190060356A1 (en) Novel ophthalmic composition and methods of use
US20180200289A1 (en) Novel ophthalmic composition and methods of use
HK1192720B (en) Ophthalmic compositions comprising providone-iodine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140730

RJ01 Rejection of invention patent application after publication